Insulin secretagogues have been widely used for managing T2DM; however, because the drug triggers insulin secretion irrespective of glucose concentrations, iatrogenic hypoglycemia remains an impediment [26,27]. The gene discussed is INS; the disease is type 2 diabetes mellitus.